Eighty-five patients undergoing cardiac surgery with cardiopulmonary bypass were given either cephalothin or ceforanide perioperatively in randomized, blinded fashion. The incidence of surgically related, postoperative infections was 23% for the cephalothin-and 26% for the ceforanide-treated groups. There were no statistically significant differences that could be identified between patients who became infected and those who remained free of infections, although the time spent in the operating theater was longer for the former group. Ceforanide achieves adequate levels in plasma and myocardial tissue that are sustained several hours after a 0.5-g parenteral dose and allows a 12-h interval between doses. Other currently available agents would have to be administered more frequently to achieve similar results.
sporin with a longer half-life than many of the cephalosporins currently marketed. Like cephalothin (Cp), it is inhibitory against microorganisms commonly associated with postoperative infection. Because of these attributes, a prospective study was undertaken to determine whether Cf given twice daily is as effective as Cp administered every 6 h when used prophylactically in cardiac surgery with cardiopulmonary bypass. (This paper was presented in part previously [W. Karney, R. Correa-Coronas, R. Zajtchuk, J. Schwartz, L. P. Smith, and E. Tramont. Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 22nd, Miami Beach, Fla., abstr. no. 764, 1982] ).
MATERIALS AND METHODS
From August 1980 to July 1981, 92 patients who were to undergo cardiac surgery with cardiopulmonary bypass at the National Naval Medical Center were admitted into the study after providing informed consent. (The study was approved by the institutional committee on human research.) Patients were not considered eligible if they had a history of penicillin allergy, received antibiotics during the 7 days before surgery, or had evidence of active infection. No one was admitted into the study if he or she declined participation for any reason or if the investigators felt the subject was unable to fully understand important aspects of the study explained in the consent form.
Patients were randomized to receive either six doses of 1 g of Cp or three doses of 500 mg of Cf and three doses of placebo according to the following schedule.
Cp or Cf was given 1 h preinduction of anesthesia (dose 1). Cp was administered again immediately after cardiopulmonary bypass was discontinued (dose 2); after completion of surgery 6 to 8 h after dose 1 (dose 3); and at 12 (dose 4), 18 (dose 5), and 24 (dose 6) h after dose 1. Cf was given 12 and 24 h after the initial dose, with placebo substituted for the active drug for doses 2, 3, and 5. The study design was not adhered to in 12 patients recorded as given Cf for dose 3 and placebo for dose 4. The pharmacy officer who prepared the antibiotic solutions for intravenous administration was the only person at the medical center who was aware of which cephalosporin each study patient received. The randomization code was not broken in any case until after the 4-to 6-week follow-up had been accomplished.
During surgery, a portion of atrial appendage was removed, and heparinized blood specimens were drawn. Tissue and plasma specimens were immediately frozen and later transported to Bristol Laboratories, Syracuse, N.Y., where cephalosporin assays were performed. Cp concentrations in plasma and tissue samples were measured using the standard cup plate bioassay method with Sarcina lutea (ATCC 9341) as the reference organism. All samples were incubated for 16 to 18 h at 330C. A high-pressure liquid chromatography system (methods are on file at Bristol Laboratories) was used to assay plasma and atrial appendage specimens for Cf concentrations. Complete blood count with differential, leukocyte count, urinalysis, and serum sodium, potassium, glucose, urea nitrogen, protein, and liver function tests were done day 1 preoperatively and day 2 postoperatively. Blood and urine cultures were obtained on postoperative days 1 and 2 and repeated as indicated. Wound cultures were done whenever indicated.
Each patient was seen preoperatively and followed 10 .4 (5.9-14) 8 .6 (5.1-12) a Thirty-three of the patients given Cp and 1 of the patients given Cf had drug levels of <2.5, which was the lower limit of the assay. n = 5 for Cp and n = 35 for Cf.
b Samples in group 1 were taken concomitantly with the removal of the atrial appendage; those in group 2 were taken immediately before bypass; those in group 3 were taken immediately after bypass, at the time the second dose of Cp was scheduled; and those in group 4 were taken at the time of skin closure. n, Number of patients. Of the patients given Cp, 2 in sample group 1, 3 in sample group 2,17 in sample group 3, and 1 in sample group 4 had drug levels of <0.5, which was the lower limit of the assay. Group 1, n = 38 for Cp and n = 37 for Cf; group 2, n = 37 for Cp and Cf; group 3, n = 24 for Cp and n = 37 for Cf; group 4, n = 38 for Cp and n = 37 for Cf. even this difference did not reach statistical significance. The mean time of surgery for the patients who were not infected was 277 min (± 64 [standard deviation]) compared with 303 min (± 78) for the infected patients (P = 0.12 by Student's t test with two-sample analysis). The only patient who had lower respiratory tract infection was in the operating theater for 480 min and required an intraaortic balloon for support in the immediate postoperative period. The other patient with infection at three separate sites had bypass grafting of three coronary vessels and replacement of the aortic valve that took 253 min, no more than the average time in surgery. There was no evidence of infection in the only patient who was explored for mediastinal bleeding during the early postoperative period.
There were no abnormalities detected in any of the routine lab tests that could be attributed to either of the study drugs. No other adverse effects due to Cp or Cf were identified in the 92 patients entered into the protocol.
DISCUSSION
In this study, the overall infection rate in patients who had cardiac surgery with cardiopulmonary bypass and who were given a cephalosporin was 25%. There was no significant difference in the infection rate between the Cf-and Cp-treated groups. However, given the study population of 85 patients, the likelihood of detecting a 15% difference in the rate of infection in the two groups was less than 0.5. In a study of similar design in which 220 patients undergoing cardiovascular surgery were enrolled, the infection rate in Cf-treated patients (14.5%) was less than the rate for those given Cp (24.5%) (R. Platt, J. Stella, J. K. Koster, J. J. Collins, L. H. Cohn, and S. Van De Vanter. Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 22nd, Miami Beach, Fla., abstr. no. 765, 1982). The lower incidence of infection in similar patients reported from other hospitals (1, 4, 9, 10) is due in part to the following: (i) not all types of postoperative, surgically related infections (e.g., respiratory and urinary tract) are included; (ii) the definition of wound infection is variable; and (iii) the extent and duration of follow-up is inadequate. The reported incidence in well-designed studies conducted at major medical centers in which all surgically related infections have been included in the analysis has been greater than 20%o (3, 6, 7) . However, the wound infection rate of 24% in these 85 patients is higher than expected after a clean surgical procedure and likely was related to technique rather than antibiotic prophylaxis. While the study was in progress, the leg wound was left open for the duration of the operation and closed at the same time as the mediastinum. After completion of the study and analysis of the data, the use of perioperative antibiotics continued, but the technique for managing phlebectomy sites was altered in the following manner. Immediately after the vein was harvested, meticulous hemostasis was established and the wound was irrigated with bacitracin solution. The fascial layers were then closed with running, absorbable sutures, and the epidermis was closed with skin staples. After this technique was initiated, one leg wound infection occurred in 100 consecutive cases.
Whether antibiotics administered in prophylactic manner effect a decrease in the infection rate in cardiac surgery patients is an issue that is not yet settled. In the only valid study comparing placebo with antibiotics in patients having valve replacement, there was no significant difference in the infection rate in the placebo versus the antibiotic-treated group, and administration of antibiotics did not prevent bacterial endocarditis (7) . However, because of the fear of prosthetic valve endocarditis, it is common practice to give perioperative antibiotics to all patients having valve replacement. The benefit of antimicrobial prophylaxis in coronary artery bypass surgery is even less well defined. Al- There is a consensus that whenever prophylaxis is used, there is no benefit in extending a course of antibiotics for longer than 48 h. after surgery (6, 8) . There is some question whether any benefit is derived from the further administration of an antimicrobial agent beyond the intraoperative period (3). The decline in infection rate seen when the technique of mang the phlebectomy site was changed after the study was completed emphasizes that surgical asepsis is the most important factor in the prevention of postoperative infections.
One ofthe.perioperative antibiotics which has been employed in an attempt to prevent infection in patients-having cardiac surgery is Cp. Cp has a broad spectrum of activity which includes coagulase-negative as well as coagulase-positive staphylococci and many of the Enterobacteriaceae. Because of its short half-life of 0.5 h, Cp is administered every 4 h when used to treat active infection. When given for prophylaxis, however, a dosage schedule after surgery of every 6 h has been employed with satisfactory results (2, 5, 6, 10 
